Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$8.1MCash on Hand
34.9mo Cash Runway
Follow SILO by emailGet an email when SILO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SILO, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Financing Silo Pharma sold 136,005 common shares at $1.50 per share and pre-funded warrants for up to 430,661 shares at $1.4999 each in a private placement that closed November 6, 2026. Net proceeds are expected to be about $815,000 for working capital. Form 8-K · SEC filing
Oct 14, 2026 ·
Deal Silo Pharma entered an asset purchase agreement with Larry King for software and related intellectual property, issuing him 150,000 shares of common stock subject to a lock-up of up to 12 months. The shares were issued in a private placement under Section 4(a)(2). Form 8-K · SEC filing
Oct 2, 2026 ·
Deal Silo Pharma entered an asset purchase agreement with Norsight Consulting to acquire software, technology and related intellectual property. Consideration is a warrant for up to 300,000 shares at $1.51, exercisable from April 1, 2027 and expiring September 30, 2031, with a 12-month lock-up on the seller's shares. Form 8-K · SEC filing
Aug 19, 2026 ·
Deal Silo Pharma entered an asset purchase agreement dated August 18, 2026 with Parkview Consulting LLC for software, technology, domain names and related IP. The seller received 165,000 unregistered common shares subject to a lock-up of up to 12 months. Form 8-K · SEC filing
Aug 17, 2026 ·
Shareholder vote Shareholders approved increasing authorized common stock from 6,666,667 to 250,000,000 shares, re-elected four directors, ratified Salberg & Company, P.A. as auditor for 2026, and approved an adjournment proposal. Form 8-K · SEC filing
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SILO holds $8.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $692,698/quarter from operations,
an estimated runway of 34.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:15 · Low
Cash runway 35 months
Shelf registration (S-3, Jan 2024) +10
Going-concern doubt in the latest 10-Q +15The positive working capital and the July 2026 Private Placement (see Note 6) and November 2026 Private Placement (see Note 8) serve to mitigate the conditions that historically raised substantial doubt about the Company’s ability to continue as a going concern.10-Q, Nov 2026
Raised after last reported balance sheet (Nov 2026) -10
Share count 2,156,292 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full SILO picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SILO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.